TY  - DATA
AU  - Stevanović, Goran
AU  - Obradović, Aleksandar
AU  - Ristić, Snezana
AU  - Petrović, Dragan
AU  - Milenković, Branislava
AU  - Mitrović, Danilo
AU  - Vignjević Filipović, Svetlana
AU  - Ilić, Katarina
AU  - Stoiljković, Vera
AU  - Lavadinović, Lidija
AU  - Pelemis, Mijomir
AU  - Petrović, Svetlana
AU  - Vidmanić, Ana
AU  - Popović, Olga
AU  - Eremić, Natasa
AU  - Sparrow, Erin
AU  - Torelli, Guido
AU  - Socquet, Muriel
AU  - Holt, Renée
AU  - Ilieva-Borisova, Yordanka
AU  - Tang, Yuxiao
AU  - Scorza, Francesco Berlanda
AU  - Flores, Jorge
AU  - Rathi, Niraj
PY  - 2020
UR  - http://intor.torlakinstitut.com/handle/123456789/637
AB  - Supplementary Table 1: Trial Scheme - Schedule of events for each participant; Supplementary Table 2: Details of Ethics committee/Institutional Review Board Overseeing  the study;
PB  - SAGE Publications
T2  - Therapeutic Advances in Vaccines and Immunotherapy
T1  - Supplementary information for the article: Stevanovic, G.; Obradovic, A.; Ristic, S.; Petrovic, D.; Milenkovic, B.; Mitrovic, D.; Vignjevic, S. F.;  Ilic, K.; Stoiljkovic, V.; Lavadinovic, L.; Pelemis, M.; Petrovic, S.; Vidmanic, A.; Popovic, O.; Eremic,  N.; Sparrow, E.; Torelli, G.; Socquet, M.; Holt, R.; Ilieva-Borisova, Y.; Tang, Y.; Scorza, F. B.; Flores,  J.; Rathi, N. Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Influenza Vaccine: A  Double Blind, Phase III Randomized Clinical Trial in Healthy Serbian Adults. Therapeutic Advances in Vaccines and Immunotherapy 2020, 8, 2515135520925336.  https://doi.org/10.1177/2515135520925336
VL  - 8
UR  - https://hdl.handle.net/21.15107/rcub_intor_637
ER  - 

@misc{
author = "Stevanović, Goran and Obradović, Aleksandar and Ristić, Snezana and Petrović, Dragan and Milenković, Branislava and Mitrović, Danilo and Vignjević Filipović, Svetlana and Ilić, Katarina and Stoiljković, Vera and Lavadinović, Lidija and Pelemis, Mijomir and Petrović, Svetlana and Vidmanić, Ana and Popović, Olga and Eremić, Natasa and Sparrow, Erin and Torelli, Guido and Socquet, Muriel and Holt, Renée and Ilieva-Borisova, Yordanka and Tang, Yuxiao and Scorza, Francesco Berlanda and Flores, Jorge and Rathi, Niraj",
year = "2020",
abstract = "Supplementary Table 1: Trial Scheme - Schedule of events for each participant; Supplementary Table 2: Details of Ethics committee/Institutional Review Board Overseeing  the study;",
publisher = "SAGE Publications",
journal = "Therapeutic Advances in Vaccines and Immunotherapy",
title = "Supplementary information for the article: Stevanovic, G.; Obradovic, A.; Ristic, S.; Petrovic, D.; Milenkovic, B.; Mitrovic, D.; Vignjevic, S. F.;  Ilic, K.; Stoiljkovic, V.; Lavadinovic, L.; Pelemis, M.; Petrovic, S.; Vidmanic, A.; Popovic, O.; Eremic,  N.; Sparrow, E.; Torelli, G.; Socquet, M.; Holt, R.; Ilieva-Borisova, Y.; Tang, Y.; Scorza, F. B.; Flores,  J.; Rathi, N. Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Influenza Vaccine: A  Double Blind, Phase III Randomized Clinical Trial in Healthy Serbian Adults. Therapeutic Advances in Vaccines and Immunotherapy 2020, 8, 2515135520925336.  https://doi.org/10.1177/2515135520925336",
volume = "8",
url = "https://hdl.handle.net/21.15107/rcub_intor_637"
}

Stevanović, G., Obradović, A., Ristić, S., Petrović, D., Milenković, B., Mitrović, D., Vignjević Filipović, S., Ilić, K., Stoiljković, V., Lavadinović, L., Pelemis, M., Petrović, S., Vidmanić, A., Popović, O., Eremić, N., Sparrow, E., Torelli, G., Socquet, M., Holt, R., Ilieva-Borisova, Y., Tang, Y., Scorza, F. B., Flores, J.,& Rathi, N.. (2020). Supplementary information for the article: Stevanovic, G.; Obradovic, A.; Ristic, S.; Petrovic, D.; Milenkovic, B.; Mitrovic, D.; Vignjevic, S. F.;  Ilic, K.; Stoiljkovic, V.; Lavadinovic, L.; Pelemis, M.; Petrovic, S.; Vidmanic, A.; Popovic, O.; Eremic,  N.; Sparrow, E.; Torelli, G.; Socquet, M.; Holt, R.; Ilieva-Borisova, Y.; Tang, Y.; Scorza, F. B.; Flores,  J.; Rathi, N. Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Influenza Vaccine: A  Double Blind, Phase III Randomized Clinical Trial in Healthy Serbian Adults. Therapeutic Advances in Vaccines and Immunotherapy 2020, 8, 2515135520925336.  https://doi.org/10.1177/2515135520925336. in Therapeutic Advances in Vaccines and Immunotherapy
SAGE Publications., 8.
https://hdl.handle.net/21.15107/rcub_intor_637

Stevanović G, Obradović A, Ristić S, Petrović D, Milenković B, Mitrović D, Vignjević Filipović S, Ilić K, Stoiljković V, Lavadinović L, Pelemis M, Petrović S, Vidmanić A, Popović O, Eremić N, Sparrow E, Torelli G, Socquet M, Holt R, Ilieva-Borisova Y, Tang Y, Scorza FB, Flores J, Rathi N. Supplementary information for the article: Stevanovic, G.; Obradovic, A.; Ristic, S.; Petrovic, D.; Milenkovic, B.; Mitrovic, D.; Vignjevic, S. F.;  Ilic, K.; Stoiljkovic, V.; Lavadinovic, L.; Pelemis, M.; Petrovic, S.; Vidmanic, A.; Popovic, O.; Eremic,  N.; Sparrow, E.; Torelli, G.; Socquet, M.; Holt, R.; Ilieva-Borisova, Y.; Tang, Y.; Scorza, F. B.; Flores,  J.; Rathi, N. Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Influenza Vaccine: A  Double Blind, Phase III Randomized Clinical Trial in Healthy Serbian Adults. Therapeutic Advances in Vaccines and Immunotherapy 2020, 8, 2515135520925336.  https://doi.org/10.1177/2515135520925336. in Therapeutic Advances in Vaccines and Immunotherapy. 2020;8.
https://hdl.handle.net/21.15107/rcub_intor_637 .

Stevanović, Goran, Obradović, Aleksandar, Ristić, Snezana, Petrović, Dragan, Milenković, Branislava, Mitrović, Danilo, Vignjević Filipović, Svetlana, Ilić, Katarina, Stoiljković, Vera, Lavadinović, Lidija, Pelemis, Mijomir, Petrović, Svetlana, Vidmanić, Ana, Popović, Olga, Eremić, Natasa, Sparrow, Erin, Torelli, Guido, Socquet, Muriel, Holt, Renée, Ilieva-Borisova, Yordanka, Tang, Yuxiao, Scorza, Francesco Berlanda, Flores, Jorge, Rathi, Niraj, "Supplementary information for the article: Stevanovic, G.; Obradovic, A.; Ristic, S.; Petrovic, D.; Milenkovic, B.; Mitrovic, D.; Vignjevic, S. F.;  Ilic, K.; Stoiljkovic, V.; Lavadinovic, L.; Pelemis, M.; Petrovic, S.; Vidmanic, A.; Popovic, O.; Eremic,  N.; Sparrow, E.; Torelli, G.; Socquet, M.; Holt, R.; Ilieva-Borisova, Y.; Tang, Y.; Scorza, F. B.; Flores,  J.; Rathi, N. Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Influenza Vaccine: A  Double Blind, Phase III Randomized Clinical Trial in Healthy Serbian Adults. Therapeutic Advances in Vaccines and Immunotherapy 2020, 8, 2515135520925336.  https://doi.org/10.1177/2515135520925336" in Therapeutic Advances in Vaccines and Immunotherapy, 8 (2020),
https://hdl.handle.net/21.15107/rcub_intor_637 .

TY  - JOUR
AU  - Stevanović, Goran
AU  - Obradović, Aleksandar
AU  - Ristić, Snezana
AU  - Petrović, Dragan
AU  - Milenković, Branislava
AU  - Mitrović, Danilo
AU  - Vignjević Filipović, Svetlana
AU  - Ilić, Katarina
AU  - Stoiljković, Vera
AU  - Lavadinović, Lidija
AU  - Pelemis, Mijomir
AU  - Petrović, Svetlana
AU  - Vidmanić, Ana
AU  - Popović, Olga
AU  - Eremić, Natasa
AU  - Sparrow, Erin
AU  - Torelli, Guido
AU  - Socquet, Muriel
AU  - Holt, Renée
AU  - Ilieva-Borisova, Yordanka
AU  - Tang, Yuxiao
AU  - Scorza, Francesco Berlanda
AU  - Flores, Jorge
AU  - Rathi, Niraj
PY  - 2020
UR  - http://intor.torlakinstitut.com/handle/123456789/616
AB  - This study was a phase III, multicenter, double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a seasonal trivalent split, inactivated influenza vaccine (TIV) in healthy Serbian adults between the ages of 18 and 65 years. This egg-based vaccine was manufactured by the Institute of Virology, Vaccines and Sera, Torlak, Belgrade, Serbia. A total of 480 participants were assigned randomly in a ratio of 2:1 to receive a single intramuscular dose (0.5 ml) of the vaccine (15 µg of hemagglutinin per strain) or placebo (phosphate-buffered saline). Participants were monitored for safety, including solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs). No SAEs related to vaccination were reported. Injection site pain (51.3%), injection site tenderness (40.4%), tiredness (17.0%), and headache (15.1%) were the most commonly reported solicited events in the vaccine group. Incidence of related unsolicited AEs was low (1.3%) among vaccinees. Hemagglutinin inhibition (HAI) titers were measured before and 21 days after vaccination in 151 participants. Overall, HAI seroconversion rates to H1 and H3 were observed in 90.1% and 76.2% of vaccinees, respectively. For B antigen, it was 51.5%, likely due to high pre-vaccination titers. Post-vaccination seroprotection rates were in the range of 78.2–95.0% for the three antigens. Post-vaccination geometric mean titers (GMT) were at least 3.8 times higher than baseline levels for all the three strains among vaccinees. Overall, the study showed that the vaccine was safe and well tolerated, and induced a robust immune response against all three vaccine strains., ClinicalTrials.gov identifier: NCT02935192, October 17, 2016
PB  - SAGE Publications
T2  - Therapeutic Advances in Vaccines and Immunotherapy
T1  - Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults
VL  - 8
DO  - 10.1177/2515135520925336
ER  - 

@article{
author = "Stevanović, Goran and Obradović, Aleksandar and Ristić, Snezana and Petrović, Dragan and Milenković, Branislava and Mitrović, Danilo and Vignjević Filipović, Svetlana and Ilić, Katarina and Stoiljković, Vera and Lavadinović, Lidija and Pelemis, Mijomir and Petrović, Svetlana and Vidmanić, Ana and Popović, Olga and Eremić, Natasa and Sparrow, Erin and Torelli, Guido and Socquet, Muriel and Holt, Renée and Ilieva-Borisova, Yordanka and Tang, Yuxiao and Scorza, Francesco Berlanda and Flores, Jorge and Rathi, Niraj",
year = "2020",
abstract = "This study was a phase III, multicenter, double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of a seasonal trivalent split, inactivated influenza vaccine (TIV) in healthy Serbian adults between the ages of 18 and 65 years. This egg-based vaccine was manufactured by the Institute of Virology, Vaccines and Sera, Torlak, Belgrade, Serbia. A total of 480 participants were assigned randomly in a ratio of 2:1 to receive a single intramuscular dose (0.5 ml) of the vaccine (15 µg of hemagglutinin per strain) or placebo (phosphate-buffered saline). Participants were monitored for safety, including solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs). No SAEs related to vaccination were reported. Injection site pain (51.3%), injection site tenderness (40.4%), tiredness (17.0%), and headache (15.1%) were the most commonly reported solicited events in the vaccine group. Incidence of related unsolicited AEs was low (1.3%) among vaccinees. Hemagglutinin inhibition (HAI) titers were measured before and 21 days after vaccination in 151 participants. Overall, HAI seroconversion rates to H1 and H3 were observed in 90.1% and 76.2% of vaccinees, respectively. For B antigen, it was 51.5%, likely due to high pre-vaccination titers. Post-vaccination seroprotection rates were in the range of 78.2–95.0% for the three antigens. Post-vaccination geometric mean titers (GMT) were at least 3.8 times higher than baseline levels for all the three strains among vaccinees. Overall, the study showed that the vaccine was safe and well tolerated, and induced a robust immune response against all three vaccine strains., ClinicalTrials.gov identifier: NCT02935192, October 17, 2016",
publisher = "SAGE Publications",
journal = "Therapeutic Advances in Vaccines and Immunotherapy",
title = "Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults",
volume = "8",
doi = "10.1177/2515135520925336"
}

Stevanović, G., Obradović, A., Ristić, S., Petrović, D., Milenković, B., Mitrović, D., Vignjević Filipović, S., Ilić, K., Stoiljković, V., Lavadinović, L., Pelemis, M., Petrović, S., Vidmanić, A., Popović, O., Eremić, N., Sparrow, E., Torelli, G., Socquet, M., Holt, R., Ilieva-Borisova, Y., Tang, Y., Scorza, F. B., Flores, J.,& Rathi, N.. (2020). Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults. in Therapeutic Advances in Vaccines and Immunotherapy
SAGE Publications., 8.
https://doi.org/10.1177/2515135520925336

Stevanović G, Obradović A, Ristić S, Petrović D, Milenković B, Mitrović D, Vignjević Filipović S, Ilić K, Stoiljković V, Lavadinović L, Pelemis M, Petrović S, Vidmanić A, Popović O, Eremić N, Sparrow E, Torelli G, Socquet M, Holt R, Ilieva-Borisova Y, Tang Y, Scorza FB, Flores J, Rathi N. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults. in Therapeutic Advances in Vaccines and Immunotherapy. 2020;8.
doi:10.1177/2515135520925336 .

Stevanović, Goran, Obradović, Aleksandar, Ristić, Snezana, Petrović, Dragan, Milenković, Branislava, Mitrović, Danilo, Vignjević Filipović, Svetlana, Ilić, Katarina, Stoiljković, Vera, Lavadinović, Lidija, Pelemis, Mijomir, Petrović, Svetlana, Vidmanić, Ana, Popović, Olga, Eremić, Natasa, Sparrow, Erin, Torelli, Guido, Socquet, Muriel, Holt, Renée, Ilieva-Borisova, Yordanka, Tang, Yuxiao, Scorza, Francesco Berlanda, Flores, Jorge, Rathi, Niraj, "Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults" in Therapeutic Advances in Vaccines and Immunotherapy, 8 (2020),
https://doi.org/10.1177/2515135520925336 . .

TY  - JOUR
AU  - Živković, Irena
AU  - Petrović, Raisa
AU  - Arsenović-Ranin, Nevena
AU  - Petrušić, Vladimir
AU  - Minić, Rajna
AU  - Bufan, Biljana
AU  - Popović, Olga
AU  - Leposavić, Gordana
PY  - 2018
UR  - http://intor.torlakinstitut.com/handle/123456789/522
AB  - The study explored influence of biological sex on development of humoral immune response to seasonal trivalent whole inactivated virus (WIV) and split virus (SV) influenza vaccines in outbred Swiss mouse model. To this end, mice of both sexes were immunized with WIV (WIV mice) and SV vaccines (SV mice) and examined for specific antibody response. Irrespective of sex, total IgG and neutralizing antibody responses to distinct virus strains were weaker in SV than in WIV mice. In WIV mice of both sexes, irrespective of strain specificity, IgG isotype response was dominated by IgG2a antibodies, while in SV mice nearly equal representation of IgG2a and IgG1 antibodies was found. The analyses of sex differences showed higher titers of H1N1-specific and both H1N1- and H3N2-specific total IgG and neutralizing antibodies in female WIV and SV mice, respectively. Additionally, sexual dimorphism in IgG subclass profile depended on vaccine type. Specifically, compared with males, in females WIV shifted IgG2a/IgG1 antibody ratio towards IgG2a isotype on the account of weaker IgG1 response, whereas in SV mice, irrespective of virus strain, IgG2a and IgG1 isotypes were equally represented in both sexes. These findings indicate the vaccine type-dependent sex bias in antibody response to inactivated influenza vaccines.
PB  - Academic Press Ltd- Elsevier Science Ltd, London
T2  - Biologicals
T1  - Sex bias in mouse humoral immune response to influenza vaccine depends on the vaccine type
EP  - 24
SP  - 18
VL  - 52
DO  - 10.1016/j.biologicals.2018.01.007
ER  - 

@article{
author = "Živković, Irena and Petrović, Raisa and Arsenović-Ranin, Nevena and Petrušić, Vladimir and Minić, Rajna and Bufan, Biljana and Popović, Olga and Leposavić, Gordana",
year = "2018",
abstract = "The study explored influence of biological sex on development of humoral immune response to seasonal trivalent whole inactivated virus (WIV) and split virus (SV) influenza vaccines in outbred Swiss mouse model. To this end, mice of both sexes were immunized with WIV (WIV mice) and SV vaccines (SV mice) and examined for specific antibody response. Irrespective of sex, total IgG and neutralizing antibody responses to distinct virus strains were weaker in SV than in WIV mice. In WIV mice of both sexes, irrespective of strain specificity, IgG isotype response was dominated by IgG2a antibodies, while in SV mice nearly equal representation of IgG2a and IgG1 antibodies was found. The analyses of sex differences showed higher titers of H1N1-specific and both H1N1- and H3N2-specific total IgG and neutralizing antibodies in female WIV and SV mice, respectively. Additionally, sexual dimorphism in IgG subclass profile depended on vaccine type. Specifically, compared with males, in females WIV shifted IgG2a/IgG1 antibody ratio towards IgG2a isotype on the account of weaker IgG1 response, whereas in SV mice, irrespective of virus strain, IgG2a and IgG1 isotypes were equally represented in both sexes. These findings indicate the vaccine type-dependent sex bias in antibody response to inactivated influenza vaccines.",
publisher = "Academic Press Ltd- Elsevier Science Ltd, London",
journal = "Biologicals",
title = "Sex bias in mouse humoral immune response to influenza vaccine depends on the vaccine type",
pages = "24-18",
volume = "52",
doi = "10.1016/j.biologicals.2018.01.007"
}

Živković, I., Petrović, R., Arsenović-Ranin, N., Petrušić, V., Minić, R., Bufan, B., Popović, O.,& Leposavić, G.. (2018). Sex bias in mouse humoral immune response to influenza vaccine depends on the vaccine type. in Biologicals
Academic Press Ltd- Elsevier Science Ltd, London., 52, 18-24.
https://doi.org/10.1016/j.biologicals.2018.01.007

Živković I, Petrović R, Arsenović-Ranin N, Petrušić V, Minić R, Bufan B, Popović O, Leposavić G. Sex bias in mouse humoral immune response to influenza vaccine depends on the vaccine type. in Biologicals. 2018;52:18-24.
doi:10.1016/j.biologicals.2018.01.007 .

Živković, Irena, Petrović, Raisa, Arsenović-Ranin, Nevena, Petrušić, Vladimir, Minić, Rajna, Bufan, Biljana, Popović, Olga, Leposavić, Gordana, "Sex bias in mouse humoral immune response to influenza vaccine depends on the vaccine type" in Biologicals, 52 (2018):18-24,
https://doi.org/10.1016/j.biologicals.2018.01.007 . .

TY  - JOUR
AU  - Milinković, Iva
AU  - Aleksić, Zoran
AU  - Janković, Saša
AU  - Popović, Olga
AU  - Bajić, Miljan
AU  - Čakić, Saša
AU  - Leković, Vojislav
PY  - 2015
UR  - http://intor.torlakinstitut.com/handle/123456789/450
AB  - Background and ObjectiveGingival recession is defined as soft and hard tissue displacement resulting in root surface exposure. The optimal outcome of gingival recession treatment is complete, predictable and long-lasting root coverage with a significant level of tissue regeneration. Tissue engineering, which applies active regeneration principles, presents the contemporary treatment approach in the restitution and regeneration of lost tissues. The objective of the present study was to evaluate and compare the clinical results of application of an autologous fibroblast cell culture (AFCC) on a collagen matrix and a connective tissue graft (CTG) placed under a coronally advanced flap (CAF), in the treatment of single and multiple gingival recessions. Material and MethodsEighteen patients from the Department of Periodontology, School of Dentistry, University of Belgrade, were randomly enrolled in this study. Inclusion criteria were the bilateral presence of Miller Class I or II single or multiple maxillary gingival recessions. A split-mouth design was used in the study. The experimental group was treated with AFCC on a collagen scaffold, which was placed under a CAF. The control group received a combination of CTG and CAF. Clinical parameters such as gingival recession coverage, keratinized tissue width, clinical attachment level and gingival index were recorded at baseline and at 12mo postoperatively. The oral hygiene level was assessed by plaque index evaluation. Postoperative healing was evaluated through the healing index, recorded 1, 2 and 3wk postoperatively. The final esthetic outcome was assessed using the mean root coverage esthetic score (RES). ResultsStatistically significant improvement of all parameters assessed was found compared with baseline. A statistically significant difference between groups was observed only in keratinized tissue width. Greater keratinized tissue width is still obtained with the use of CTG. Regarding the tissue-healing results, no statistically significant difference was achieved. The RES results were similar for both groups. ConclusionsWithin the limitations of the present study, both procedures proved to be efficient in gingival recession treatment. AFCC, as a novel tissue-engineering concept and living cell-based therapy, proved to be a reliable and successful treatment concept.
PB  - Wiley, Hoboken
T2  - Journal of Periodontal Research
T1  - Clinical application of autologous fibroblast cell culture in gingival recession treatment
EP  - 370
IS  - 3
SP  - 363
VL  - 50
DO  - 10.1111/jre.12215
ER  - 

@article{
author = "Milinković, Iva and Aleksić, Zoran and Janković, Saša and Popović, Olga and Bajić, Miljan and Čakić, Saša and Leković, Vojislav",
year = "2015",
abstract = "Background and ObjectiveGingival recession is defined as soft and hard tissue displacement resulting in root surface exposure. The optimal outcome of gingival recession treatment is complete, predictable and long-lasting root coverage with a significant level of tissue regeneration. Tissue engineering, which applies active regeneration principles, presents the contemporary treatment approach in the restitution and regeneration of lost tissues. The objective of the present study was to evaluate and compare the clinical results of application of an autologous fibroblast cell culture (AFCC) on a collagen matrix and a connective tissue graft (CTG) placed under a coronally advanced flap (CAF), in the treatment of single and multiple gingival recessions. Material and MethodsEighteen patients from the Department of Periodontology, School of Dentistry, University of Belgrade, were randomly enrolled in this study. Inclusion criteria were the bilateral presence of Miller Class I or II single or multiple maxillary gingival recessions. A split-mouth design was used in the study. The experimental group was treated with AFCC on a collagen scaffold, which was placed under a CAF. The control group received a combination of CTG and CAF. Clinical parameters such as gingival recession coverage, keratinized tissue width, clinical attachment level and gingival index were recorded at baseline and at 12mo postoperatively. The oral hygiene level was assessed by plaque index evaluation. Postoperative healing was evaluated through the healing index, recorded 1, 2 and 3wk postoperatively. The final esthetic outcome was assessed using the mean root coverage esthetic score (RES). ResultsStatistically significant improvement of all parameters assessed was found compared with baseline. A statistically significant difference between groups was observed only in keratinized tissue width. Greater keratinized tissue width is still obtained with the use of CTG. Regarding the tissue-healing results, no statistically significant difference was achieved. The RES results were similar for both groups. ConclusionsWithin the limitations of the present study, both procedures proved to be efficient in gingival recession treatment. AFCC, as a novel tissue-engineering concept and living cell-based therapy, proved to be a reliable and successful treatment concept.",
publisher = "Wiley, Hoboken",
journal = "Journal of Periodontal Research",
title = "Clinical application of autologous fibroblast cell culture in gingival recession treatment",
pages = "370-363",
number = "3",
volume = "50",
doi = "10.1111/jre.12215"
}

Milinković, I., Aleksić, Z., Janković, S., Popović, O., Bajić, M., Čakić, S.,& Leković, V.. (2015). Clinical application of autologous fibroblast cell culture in gingival recession treatment. in Journal of Periodontal Research
Wiley, Hoboken., 50(3), 363-370.
https://doi.org/10.1111/jre.12215

Milinković I, Aleksić Z, Janković S, Popović O, Bajić M, Čakić S, Leković V. Clinical application of autologous fibroblast cell culture in gingival recession treatment. in Journal of Periodontal Research. 2015;50(3):363-370.
doi:10.1111/jre.12215 .

Milinković, Iva, Aleksić, Zoran, Janković, Saša, Popović, Olga, Bajić, Miljan, Čakić, Saša, Leković, Vojislav, "Clinical application of autologous fibroblast cell culture in gingival recession treatment" in Journal of Periodontal Research, 50, no. 3 (2015):363-370,
https://doi.org/10.1111/jre.12215 . .